Novamab

NovaMab (Shanghai Novamab Biopharmaceuticals Co., Ltd.) is a clinical-stage biotech company founded in 2017 and headquartered in the Shanghai International Medical Park, Pudong New Area, Shanghai, China. The company is dedicated to creating life-changing therapies through innovative VHH (single domain antibody) technology, with a highly differentiated pipeline targeting high-potential markets including asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD). NovaMab's most advanced program, an inhaled IL-4R VHH antibody (LQ036), has progressed to Phase IIb clinical trials, while its inhaled TSLP VHH (LQ043H) is entering Phase IB studies. The company operates a 500L GMP workshop for VHH antibody production using Pichia pastoris, holds over 100 patents, and has been recognized among China's top 50 innovative biopharmaceutical enterprises.